Zivo Bioscience Joins Russell Microcap® Index

Rhea-AI Summary

ZIVO Bioscience, Inc. (NASDAQ: ZIVO) has been added to the Russell Microcap® Index as of June 27, 2022, following the annual reconstitution. This membership will last for one year and enhances ZIVO's visibility among institutional investors, aiming to boost growth expectations. The Russell indexes, benchmarked by $12 trillion in assets, reflect market capitalization and style. CEO John Payne expressed optimism about increased investor interest and broadened stock exposure through this inclusion, which aligns with the company's ongoing strategy in biotech and agtech sectors.

Positive

• Inclusion in the Russell Microcap® Index enhances visibility to institutional investors.
• Reflects market confidence and growth expectations for ZIVO's business strategy.
• Potential for increased stock exposure due to membership in growth and value style indexes.

Negative

• None.

BLOOMFIELD HILLS, Mich.--(BUSINESS WIRE)-- ZIVO Bioscience, Inc. (NASDAQ: ZIVO) (the “Company”), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, today announced that, effective today, June 27, 2022, it has joined the Russell Microcap® Index (^RUMIC) as a result of the 2022 Russell indexes annual reconstitution.

Membership in the Russell Microcap® Index, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes.

“We are pleased to be added to the Russell Microcap® Index this year. Our inclusion reflects continued interest in our stock along with long- and near-term growth expectations as we evolve and execute on our business strategy. I also look forward to expanding our stock’s exposure to a broader investor audience, including more institutional investors, as a result of ZIVO’s inclusion,” stated John Payne, President and Chief Executive Officer of ZIVO Bioscience.

Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately $12 trillion in assets are benchmarked against Russell’s US indexes. Russell indexes are part of FTSE Russell, a leading global index provider.

For more information on the Russell Microcap® Index and the Russell indexes reconstitution, go to the “Russell Reconstitution” section on the FTSE Russell website.

About ZIVO Bioscience, Inc.

ZIVO Bioscience is a research and development company operating in both the biotech and agtech sectors, with an intellectual property portfolio comprised of proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques and patented or patent-pending inventions for applications in human and animal health. Please visit www.zivobioscience.com for more information.

About FTSE Russell

FTSE Russell is a global index leader that provides innovative benchmarking, analytics and data solutions for investors worldwide. FTSE Russell calculates thousands of indexes that measure and benchmark markets and asset classes in more than 70 countries, covering 98% of the investable market globally.

FTSE Russell index expertise and products are used extensively by institutional and retail investors globally. Approximately $20 trillion is currently benchmarked to FTSE Russell indexes. For over 30 years, leading asset owners, asset managers, ETF providers and investment banks have chosen FTSE Russell indexes to benchmark their investment performance and create ETFs, structured products and index-based derivatives.

A core set of universal principles guides FTSE Russell index design and management: a transparent rules-based methodology is informed by independent committees of leading market participants. FTSE Russell is focused on applying the highest industry standards in index design and governance and embraces the IOSCO Principles. FTSE Russell is also focused on index innovation and customer partnerships as it seeks to enhance the breadth, depth and reach of its offering.

FTSE Russell is wholly owned by London Stock Exchange Group.

For more information, visit www.ftserussell.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220627005035/en/

ZIVO Bioscience, Inc.

Keith Marchiando, Chief Financial Officer

(248) 452-9866 x 130

kmarchiando@zivobioscience.com

LHA Investor Relations

Tirth T. Patel

(212) 201-6614

tpatel@lhai.com

Source: ZIVO Bioscience, Inc.

FAQ

What impact does ZIVO's inclusion in the Russell Microcap® Index have?

ZIVO's inclusion enhances its visibility to institutional investors and reflects positive growth expectations.

When did ZIVO join the Russell Microcap® Index?

ZIVO joined the Russell Microcap® Index on June 27, 2022.

How long will ZIVO be included in the Russell Microcap® Index?

ZIVO's membership in the Russell Microcap® Index is effective for one year.

What does membership in the Russell Microcap® Index mean for ZIVO?

Membership means automatic inclusion in growth and value style indexes, which can attract more institutional investment.